Achilles Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	34	36	37	203	-	-
Market Cap Growth	30.07%	-1.60%	-81.89%	-	-	-
Enterprise Value	-74	-91	-128	-51	-162	-97
PE Ratio	-	-0.52	-0.52	-3.33	-	-
PB Ratio	0.26	0.26	0.19	0.70	-	-
P/FCF Ratio	-1.03	-0.73	-0.55	-3.04	-	-
P/OCF Ratio	-1.06	-0.75	-0.62	-3.43	-	-
EV/EBITDA Ratio	0.96	1.41	1.90	0.88	4.99	7.09
EV/EBIT Ratio	0.89	1.31	1.80	0.83	4.88	6.94
EV/FCF Ratio	1.16	1.83	1.91	0.76	4.36	6.44
Debt / Equity Ratio	0.03	0.03	0.04	0.04	0.08	0.00
Debt / EBITDA Ratio	-0.07	-0.07	-0.13	-0.21	-0.49	-0.04
Debt / FCF Ratio	-0.09	-0.09	-0.13	-0.18	-0.43	-0.03
Quick Ratio	8.23	7.74	9.63	13.94	10.70	25.30
Current Ratio	9.63	8.57	10.93	14.90	11.30	26.72
Return on Equity (ROE)	-43.00%	-42.60%	-31.70%	-22.30%	-22.80%	-
Return on Assets (ROA)	-37.90%	-37.50%	-28.50%	-20.30%	-20.50%	-
Return on Capital (ROIC)	-52.77%	-51.20%	-38.12%	-21.27%	-16.42%	-13.53%
Earnings Yield	-188.10%	-192.15%	-193.18%	-30.04%	-	-
FCF Yield	-144.34%	-136.66%	-181.97%	-32.90%	-	-
Buyback Yield / Dilution	-1.38%	-2.13%	-36.59%	-2587.54%	-66.03%	-
Total Shareholder Return	-1.38%	-2.13%	-36.59%	-2587.54%	-66.03%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).